NCT06719219View on ClinicalTrials.gov

A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Staphylococcus (S.) Aureus Infection
Interventions
BIOLOGICAL

LTB-SA7

LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.

BIOLOGICAL

Placebo

Sodium Phosphate with Sodium Chloride

Trial Locations (1)

20889

Naval Medical Research Command Clinical Trial Center, Bethesda

Sponsors
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

collaborator

Wellcome Trust

OTHER

collaborator

Navy Medical Research Command (NMRC)

UNKNOWN

lead

LimmaTech Biologics AG

INDUSTRY

NCT06719219 - A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. | Biotech Hunter | Biotech Hunter